CHINA FOCUS
BIOTECH WEEK BOSTON

Connect with Chinese Pharma and Investors in Biotech Innovation

Hynes Convention Center 102
Sept 4-6, 2018
Dear friends,

On behalf of the MyBioGate team, I would like to welcome you to China Focus Forum, a platform to exchange ideas and foster collaborations across the Pacific.

With a rising aging population, a thriving economy, as well as encouraging policies, China has embraced a vigorously growing healthcare market in the past decade. Chinese biotech and pharma are seeking cross-border collaborations to provide a better quality of care to this large population. On the other hand, China, once a backwater when it came to biotech, has rapidly become a focus of investment and innovation, and has attracted a full spectrum of attention, curiosity, skepticism, and expectations. It all calls for this CHINA FOCUS Forum where both China and the western community can have a focused discussion on cross-border collaboration.

As a professional service entity, MyBioGate has a mission to bridge China and overseas healthcare innovations. MyBioGate not only supports pharmaceuticals and investors with their overseas strategies, by circulating insights about healthcare breakthroughs and publishing industry research reports; but also organizes forums and other partnering events to bring together healthcare executives across the Pacific for real business conversations. Our goal is to foster healthcare innovations that could benefit the world through alliances between the east and the west.

China Focus is designed to be a meaningful platform, where the U.S. and the Western healthcare companies can come to learn about China and Chinese companies, to meet decision makers, and to initiate business conversations that otherwise difficult to start.

Thank you to each of our speakers. The caliber of the speaker list is extraordinary and we are fortunate to have you involved. I cannot express how much your participation means.

Finally, I would like to thank everyone who makes it here. Your active involvement in the online partnering platform has impressed everyone in our team and we are glad we could be helpful to companies and individuals like you.

Please enjoy yourself in this three-day event. If there is anything our team can do to be of assistance, don’t hesitate to ask. We look forward to seeing you again at our upcoming events in NYC in October and San Francisco in January.

Sincerely,

General Manager (China),
MyBioGate Inc.
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept 5th</td>
<td>10:00-12:00</td>
<td>Registration</td>
<td>Haisheng Wang, General Manager (China), Mybiogate Inc.</td>
</tr>
<tr>
<td></td>
<td>13:30-13:40</td>
<td>Opening Remarks</td>
<td>Haisheng Wang, General Manager (China), Mybiogate Inc.</td>
</tr>
<tr>
<td></td>
<td>13:40-14:10</td>
<td>Novel Drugs To Enter China Under CFDA Reform: Opportunities And Challenges</td>
<td>Haisheng Wang, General Manager (China), Mybiogate Inc.</td>
</tr>
<tr>
<td></td>
<td>14:10-14:35</td>
<td>Current Status And Outlook Of Immunotherapy In China</td>
<td>Qiang Lu, Chairman, Gentiant Pharmaceutical</td>
</tr>
<tr>
<td></td>
<td>14:35-15:00</td>
<td>New Drug Innovations In China And Its Unique Opportunities For Investment And Partnering</td>
<td>Lynn Yang, Managing Director, Sequoia Capital China</td>
</tr>
<tr>
<td></td>
<td>15:00-15:25</td>
<td>Chinese Big Pharma’s Strategy In Drug Development</td>
<td>Ai-min Hui (Tdb), CMO, Fosun Pharma</td>
</tr>
<tr>
<td></td>
<td>15:50-16:10</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16:55-17:40</td>
<td>Panel Discussion 2: China Focus: Cross-border Investment And Collaboration</td>
<td>Douglas Thien (Moderator), Immunologic Therapeutics China, Strategic Advisor</td>
</tr>
<tr>
<td></td>
<td>8:00-9:30</td>
<td>1-to-1 Meetings</td>
<td>Ginger Ding, Director Of Research, Mybiogate Inc.</td>
</tr>
<tr>
<td></td>
<td>9:30-9:45</td>
<td>Showcase: Industry Research Report Of Pd-1tcr1 Combo Therapies</td>
<td>Feng Tian, Chief Scientific Officer, ambix</td>
</tr>
<tr>
<td></td>
<td>10:05-10:25</td>
<td>Bispecific Antibodies For Cancer Immunotherapy: Design Strategies And Development Challenges</td>
<td>Jinming Gu, Head Of Biologics Development</td>
</tr>
<tr>
<td></td>
<td>10:25-11:00</td>
<td>Panel Discussion 3: Current Status And Outlook Of I.O. Drug Development</td>
<td>Patricio Theoharis, CEO &amp; CSO, Cell Medica</td>
</tr>
<tr>
<td></td>
<td>11:00-11:20</td>
<td>Neuroscience Drug Discovery: Current Frontiers And Future Perspectives</td>
<td>Patrick Liu, Executive Vice President, Simeone Pharmaceutical Group</td>
</tr>
<tr>
<td></td>
<td>11:20-12:00</td>
<td>Company Pitch</td>
<td>Phasebio / Immunologic Therapeutics / OR Pharma</td>
</tr>
<tr>
<td></td>
<td>12:00-13:30</td>
<td>Lunch Break And 1-to-1 Meetings</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:30-13:45</td>
<td>Showcase: Industry Research Report Of Car-t1tcr1</td>
<td>Miguel Forte, CEO, Zelluna Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>13:45-14:05</td>
<td>Lymphocyte Adoptive Cell Therapy In Oncology: Challenges And Opportunities</td>
<td>Stefanos Theoharis, CEO &amp; CSO, Cell Medica</td>
</tr>
<tr>
<td></td>
<td>14:05-14:25</td>
<td>Development Of Allogeneic, Off-the-shelf Car-t Treatments For Hematological Malignancies And Solid Tumors</td>
<td>Stefanos Theoharis, SVP Corporate Development And Partnering Cell Medica</td>
</tr>
<tr>
<td></td>
<td>14:25-14:45</td>
<td>Car-t Cell Therapeutics For The Treatment Of Solid Tumor</td>
<td>Zonghai Li, CFO &amp; CSO, Carigen Therapeutics</td>
</tr>
<tr>
<td></td>
<td>14:45-15:30</td>
<td>Panel Discussion 4: Adoptive Cell Transfer: Innovations And Global Collaborations</td>
<td>Patricio Theoharis, CEO &amp; CSO, Cell Medica</td>
</tr>
<tr>
<td></td>
<td>15:30-16:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16:00-16:10</td>
<td>Showcase: Synageva's Experience In Developing Karuna’s Orphan Disease Drugs</td>
<td>Zhanlin Xia, Founder &amp; CSO, Abimmune Bio</td>
</tr>
<tr>
<td></td>
<td>16:10-16:50</td>
<td>Company Pitch</td>
<td>Nawaiant Therapeutics / Ayass Bioscience LLC</td>
</tr>
<tr>
<td></td>
<td>16:50-18:00</td>
<td>1-to-1 Meetings</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18:00-17:00</td>
<td>1-to-1 Meetings</td>
<td></td>
</tr>
</tbody>
</table>
NOVEL DRUGS TO ENTER CHINA UNDER CFDA REFORM: OPPORTUNITIES AND CHALLENGES

HAISHENG WANG
General Manager (China), MyBioGate

Dr. Haisheng (Hank) Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Prior to Joining MyBioGate, Hank was Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group. Before that, Hank served many leading domestic pharmaceutical and life science companies including China Fortune, Biokine, BioDuro, with rich experience in new drug R&D, CRO, and medicinal chemistry. Hank is also President of American Association of Pharmaceutical Scientists (AAPS) China Discussion Group, the Vice Chairman of the Committee of China Quality Association for Pharmaceuticals Sinoo Generic Pharmaceuticals Association (SGPA), adjunct professor and master supervisor of Peking University School of Pharmaceutical Sciences (SPS), committee member of China Medicinal Biotechnology Association (CMBA), China Association of Biomedical Information technology, was presented with the first prize of scientific and technological progress by China Association of Chinese Medicine (CACM).

CURRENT STATUS AND OUTLOOK OF IMMUNOTHERAPY IN CHINA

QIANG LV
Chairman, Genfleet Pharmaceutical

Dr. Qiang Lu is the founder and chairman of GenFleet Therapeutics Inc., a Shanghai based immune therapy company focusing on the next generation of immuno-oncology and autoimmune drug development. Dr. Lu also founded WuXi AppTec’s Biology and Biologics business units, as VP of Research. Prior to that, Dr. Lu worked in US at Wyeth and Novartis, respectively, as a project leader and a platform leader. Dr. Lu obtained his BS (Biology) in Peking University and PhD (Biochemistry) in Brandeis University before finishing a postdoc training (Physiology) in Tufts Medical School. Dr. Lu had championed numerous clinical stage product discovery and development while serving for various pharmaceutical or biotech companies, including PD-L1 (Mab), MK1, and URAT1 (at CStone Pharmaceuticals as SVP of Operation), PD-1 (Mab, at Gloria Pharmaceuticals as CSO, with ex-China rights transferred to Arcus Biosci.), Orexin antagonist YZJ-1139 and EGFR/T790M YZJ-0318 (at Yangtze River Pharmaceuticals as CSO), among others.

NEW DRUG INNOVATIONS IN CHINA AND ITS UNIQUE OPPORTUNITIES FOR INVESTMENT AND PARTNERING

LYNN YANG
Managing Director, Sequoia Capital China

Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May 2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry such as Burning Rock, Cstone, JW Therapeutics, Grail, Hong Kong Asia Medical etc. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare. Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.

CHINESE BIG PHARMA’S STRATEGY IN DRUG DEVELOPMENT COLLABORATION

AI-MIN HUI
CMO, Fosun Pharma

Aimin Hui, MD, PhD is the Chief Medical Officer and a Senior Vice-President of Fosun Pharma Group, a leading Chinese pharmaceuticals headquartered in Shanghai. At Fosun Dr. Hui is leading global research, development and regulatory affairs across all business segments including pharmaceuticals, diagnostics and medical devices. Dr. Hui is an oncologist with 30 years experiences in academia and industry, and dedicated on drug development for the last 20 years. In 2000, Dr. Hui joined National Cancer Institute, NIH where he was instrumental in oncology drug development for 7 years, in collaboration with multiple pharmaceuticals and gained comprehensive hands-on experiences in pre-clinical, translational and early phase clinical development. He then joined Cephalon in 2009 (acquired by Teva), and then Millennium/Takeda in 2010. At Takeda, Dr. Hui led the clinical development and global submission for ixazomib (Ninlaro) from first-in-human trial to FDA approval in November 2015 for 6 years. He also pioneered a fast registration path in China by adding a pre-specified Chinese patient cohort onto the ixazomib global phase 3 trial Tourmaline-MM1. With this approach, ixazomib has been approved in China just over 2 years after FDA’s approval.

LIVZON MABPHARM: COMPANY INTRODUCTION AND GLOBAL DEVELOPMENT STRATEGY

JOHN CHEN
Director of Business Development, Livzon Mabpharm, Inc

John Chen, MD/MBA, Senior Director of Business and Corporate Development. John has over 14 years of capital market operation experience with successful IPO and deal execution track record.

BUILDING NEXT GENERATION BIOLOGICS USING EXPENDED GENETIC CODE

FENG TIAN
Chief scientific Officer, Ambrx

Previously, as Chief Scientific Officer, Dr. Tian oversaw the company’s research and development teams. He played a key role in the establishment of the EuCODE technology platform (site-specific non-natural amino acid incorporation in eukaryotic cells); he led teams to establish Ambrx’s site-specific antibody drug conjugate (ADC) technology platform, the ADC pipeline, and the “Life Switch” vaccine platform. Dr. Tian also initiated and established the Ambrx China Strategy. He played a central role in building China collaborations, and more recently, in Ambrx strategic transactions in 2015.

Prior to joining Ambrx, Dr. Tian conducted his postdoctoral study at The Scripps Research Institute in Professor Peter G. Schultz’s group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors.
**PANEL DISCUSSION 1: RISE OF CHINESE HEALTHCARE MARKET**

**REBECCA ROBBINS (MODERATOR)**  
Business Reporter, STAT News

Rebecca Robbins is a reporter covering the life sciences industry, focusing on the San Francisco Bay Area and China. She reports from San Francisco. She previously reported as an intern for the Washington Post, the Hartford Courant, and the Santa Barbara Independent. Rebecca earned a history degree at Harvard University, where she spent a year as managing editor of the Harvard Crimson.

**ANJIANG (VINCENT) LIU**  
Senior Advisor Wanbang Biopharmaceutical, Deputy General Manager, Strategic Product Development Center, Fosun Pharma

Dr. Liu worked in International Business Division and Wanbang Biopharmaceutical of Shanghai Fosun Pharmaceutical Group in 2009. His achievements include helping the company to raise a $500 million private equity fund from overseas and setting up two JVs with large US and Canadian companies in China, investment in healthcare service company in the US and completed several pharmaceutical business development transactions which could potentially bring to Chinese market total over $1 billion revenue product opportunities in the future.

**YUANHUA DING**  
Head of External R&D Innovation - Asia, Pfizer Worldwide Research & Development

Dr. Yuan-Hua Ding is an Executive Director and Head of Pfizer External Science & Innovation (ES&I) – Asia/Pacific, Pfizer Worldwide Research & Development (WRD). He is also a member of the ES&I leadership team. In this capacity, he and his team partner with colleagues in ES&I, Pfizer Business Development Group, Pfizer Venture Group and Pfizer Asia Country Offices to evaluate technologies and assets from academic, biotech & pharma laboratories, seek opportunities to incubate early biotech companies, build and manage an external network of academic institutes, biotech & pharma companies, and venture capital groups as well as regional bioparks. He liaises with therapeutic area and technology research unit leaders in accessing the sciences, technologies and products needed to support Pfizer R&D mission. Dr. Ding also manages WRD’s Asia Innovation Fund which enables academic collaborations, biotech alliances and NewCo seeding with Asia partners.

**NOEL GODDARD**  
Principal, Accelerate NY Seed Fund

Noel is a Principal for the Accelerate NY Seed Fund where she evaluates and performs diligence on applicant companies and their technologies. Prior to her role with Accelerate NY, Noel directed the formulation R&D for Symbiotic Health, a NYC startup company focused on oral drug delivery of cellular and biologic therapeutics for diseases lower GI tract. She also founded a food safety diagnostics company in Calverton, NY, and worked with Sapling Learning, a STEM educational software startup acquired by Macmillan Learning.

**PANEL DISCUSSION 2: CHINA FOCUS: CROSS-BORDER INVESTMENT AND COLLABORATION**

**DOUGLAS THIEN (MODERATOR)**  
Immunotherapeutics, China Strategic Advisor

**KIM NEARING**  
Managing Director, Cedrus Group

Kimberly Nearing has over 20 years of life sciences experience, including in the capacity as a senior operations manager, an investor, an investment banker and a consultant. Currently, as the Managing Director, Head of Life Sciences at the Cedrus Group, a global boutique investment firm headquartered in Hong Kong with offices in Shanghai, and Beijing, Kim is actively engaged in international business and finance activities, particularly in the Greater China and the Gulf Cooperation Council (GCC) regions. She is also the regional leader (NY/NJ/PA) for BayHelix, an invitation-only organization of leaders of Chinese heritage in the global life sciences and healthcare community.

She was previously the Managing Partner of Phoenixian Venture Partners, a late-stage biotechnology venture capital fund, and she had held various management positions at Amgen, Merck, and IBM’s Healthcare Group.

**CHONG XU**  
Senior Associate, F-Prime Capital Partners

Chong is a Senior Associate at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

**YAN ZHANG**  
Principal at Delos Capital

Dr. Yan Zhang has over 6 years of healthcare-related experience. Currently he is responsible for US healthcare investment and portfolio management at Cowin Capital. Previously, he worked at BGI, the leading genome sequencing provider worldwide, and completed a few private placement transactions in healthcare related sectors, including bio-pharmaceutical, Med-Tech, healthcare Services, etc. He developed close relationship with many large and medium-sized healthcare companies. Dr. Zhang holds a Ph.D. in Genetics from University of Iowa, and B.S. of Biology from Fudan University from University of Iowa, and B.S. of Biology from Fudan University.

**BOB AI**  
SVP, The Trout Group

Bob is a SVP of the Trout Group. He focuses on the Sino-US cross-border banking and strategic consulting service (mainly licensing) and investor relations. Prior to joining Trout in September 2016, he was managing director, senior biotech analyst at WallachBeth Capital. Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE MKT listed Chinese specialty pharmaceutical company. He has also served as Principal in crossover life science private equity firm Merlin Nexus and senior equity analysts at assets management firms Bennett Lawrence and Merlin Biomed Group.

Bob received his PhD and MBA from Penn State University and did postdoctoral training at University of Pennsylvania. He has published eight articles in peer-reviewed scientific journals. He also won the prestigious Ray Wu scholarship for outstanding Chinese Student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.
AGENDA

BISPECIFIC ANTIBODIES FOR CANCER IMMUNOTHERAPY:
DESIGN STRATEGIES AND DEVELOPMENT CHALLENGES

JINMING GU
Head of Biologics Development at Abpro labs;
Former Executive Director of Biologics Discovery at
Shanghai HengRui Pharmaceuticals

Dr. Jinming Gu obtained his Ph.D. degree in Molecular Biology from Vanderbilt University. He then joined Dana-Farber Cancer Institute/Harvard Medical School for a postdoctoral training in oncology. Dr. Gu started his industry career at Merck & Co., Inc., where he worked on MM111, a bispecific antibody later moved into clinical trials. He then joined Abbott Laboratories. Since joining Abbott/Abbvie, he has been leading/working on multiple mAb, ADC, and bispecific antibody programs, including ABT-806, ABT-414, ABT-165, and ABVB642 etc. Dr. Gu then became the Executive Director of Biologics Discovery at Shanghai Hengrui Pharmaceutical Co., Ltd., a leading innovative pharmaceutical company in China, where he established a world-class antibody discovery platform including automated human naive antibody phage display screening platform and a yeast display antibody optimization platform in addition to delivering multiple next generation antibody-based therapeutic candidates (including ADC, bsAb, and mAb) into clinical development, including SHR-1701. Dr. Gu is current the head of Biologics Development at Abpro labs, an innovative biotech in US, where he oversees innovative biologics for cancer immunotherapy.

NEUROSCIENCE DRUG DISCOVERY:
CURRENT FRONTIERS AND FUTURE PERSPECTIVES

ZHENHUA WU
CEO, NeuExcell Therapeutics

Dr. Wu is a senior discovery and development leader with more than 20 years’ experience and a deep understanding of the R&D value chain. He is currently the CEO of NeuExcell Therapeutics. Previously he was the Vice President, Head of Preclinical Development of United Neuroscience, overseeing strategy and execution of preclinical research and development. Prior to UNS, he was Director of Neuroscience Therapeutic Area at GlassSmithKline, where he served as a global project lead focusing on therapies for neurodegenerative and neuroinflammatory diseases. He was responsible for directing virtual drug discovery pipeline through partnering with external groups, such as biotech, academic groups and CROs, toward to proof-of-concept studies. Dr. Wu had worked in various functional areas in Merck & Co. for ten years where he led various neuroscience projects and delivered several preclinical candidates and served as a global externalization lead. Zhenhua received his Ph.D. degree in neuroscience from University of Rochester and M.S. degree in cell biology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences. He has published extensively in the field of neuroscience including publications in prestigious journals such as Nature, Nature Medicine, Neuron and Stroke. He is also a recipient of Hugh Davson Distinguished Award in Neurovascular Biology. Zhenhua serves as the President (2017-2018) of Sino-American Pharmaceutical Professional Association – Great Philadelphia (SAPA-GP).

PANEL DISCUSSION 3: CURRENT STATUS AND OUTLOOK OF I.O. DRUG DEVELOPMENT

JINMING GU
Head of Biologics Development at Abpro labs;
Former Executive Director of Biologics Discovery at Shanghai HengRui Pharmaceuticals

WENRU SONG
co-founder, President and Head of R&D of Kira Pharmaceuticals
Former global VP and global clinical leader of Immuno-Oncology development at AstraZeneca Global Medicines

Dr. Song is the co-founder, President and Head of R&D of Kira Pharmaceuticals, a new biotech startup based on cutting-edge immunological sciences. Dr. Song was most recently as the global VP and global clinical leader of Immuno-Oncology development at AstraZeneca Global Medicines. Previously, Dr. Song was the Head of Regional Oncology Development in Asia-Pacific at Millennium/Takeda Oncology, and global clinical lead at Pfizer Immuno-oncology. Prior to joining the pharma-industry, he was an associate investigator at Baylor Institute of Immunology Research and an attending oncologist physician at Baylor Sammons Cancer Center.

JIAN IRISH
Global Head of Manufacturing, Kite Pharma

Jian Iris has held various leadership roles in the biopharma industry with the responsibilities for product development, launch, supply, and lifecycle management. Jian has served executive leadership roles in launching the cell therapy at Kite Pharma as the Global Head of Manufacturing and Senior Vice President of Supply Chain. Prior to Kite Pharma, she held Vice President Responsibility for Biologics Supply, Sourcing, Partnerships and Biologics Product Development at Sanofi. Jian also served executive leadership roles at Amgen in the JAPAC regional operations, Supply Chain, Manufacturing, and oncology CMC development.
LYMPHOCYTE ADOPTIVE CELL THERAPY IN ONCOLOGY: CHALLENGES AND OPPORTUNITIES

MIGUEL FORTE
CEO, Zelluna Immunotherapy; Chair, Commercialization Committee at ISCT

Currently the CEO of Zelluna Immunotherapy and visiting Professor at the Lisbon and Aveiro Universities in Portugal. Currently also serving as Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cell and Gene Therapy (ISCT). From February 2006 to January 2010 was VP of Global Medical Affairs at UCB. In 2004 joined Nabi Pharmaceuticals as the VP of Clinical, Medical and Regulatory Affairs in Europe. After several clinical, academic and regulatory positions in the public sector in Portugal and at the EMA, spent six years with Bristol-Myers Squibb in various positions including Country Medical Director, Executive Director of Infectious Diseases, Immunology and Dermatology and VP of International Medical Organization in Portugal and Belgium. Holds an M.D. from the Faculty of Medicine of the University of Lisbon, Portugal, and a Ph.D. in Immunology from the University of Birmingham, UK, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies (HEP). He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.

CAR-T CELL THERAPEUTICS FOR THE TREATMENT OF SOLID TUMOR

ZONGHAI LI
CEO & CSO, CARsgen Therapeutics

Zonghai Li, MD, Ph.D., is the founder of CARsgen Therapeutics and CEO since the company’s inception in 2014. Prior to CARsgen, Dr. Li founded a series of biotech start-ups in China. He is now the tenure Professor at Shanghai Cancer Institute, Renji Hospital affiliated to Shanghai JiaoTong University, member of Standing Committee of Gene Therapy Association of China, China Translational Medicine Union, and Shanghai Immunology Association. Graduated from Hunan Medical University (Now Xiangya School of Medicine, Central South University) in 1997, he further acquired his PhD degree from Fudan University in 2005.

DEVELOPMENT OF ALLOGENEIC, OFF-THE-SHELF CAR-T TREATMENTS FOR HEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS

STEFANOS THEOHARIS
SVP Corporate Development and Partnering, Cell Medica

Stefanos joined Cell Medica to lead its partnering activities, bringing a combination of academic, business development, project management and finance skills. Following his PhD, Stefanos worked as a post-doctoral researcher at Imperial College, whilst also working for six years in parallel as a paid consultant to the London Technology Network, a government-funded organization bridging the gap between industry and academia. Subsequently, Stefanos joined Lazard, the investment bank, as a member of the life science M&A team and then Roche Partnering, as Director of Emerging Technologies, where he participated in multiple licensing deals, with a focus on novel innovative technologies. He then joined Antisense Pharma as Head of BD. Prior to joining Cell Medica, Stefanos was CBO for apceth in Munich, where he was responsible for business development on the company’s first-in-man engineered cell therapy platform and its GMP manufacturing business, as well as project management, and communications. Stefanos holds a PhD in gene therapy and Immunology and a MSc in Molecular Medicine both from Imperial College.

SHOWCASE: SYNAGEVA’S EXPERIENCE IN DEVELOPING KANUMA’S ORPHAN DISEASE DRUGS

ZHINAN XIA
Founder and CSO, Abimmune Bio

Previous Director, Synageva BioPharma Corp.

Dr. Xia received his PhD degree in Biochemistry and Molecular Biology from University of Kentucky followed by postdoc training at Harvard Medical School in molecular immunology/oncology. He is the first scientist expressed active form of human granzyme B (T cell’s molecular knife to kill tumor and viral infected cells). Dr Xia joined Dana-Farber Cancer Institute as staff scientist/instructor in 2000 to lead MHC tetramer core facility to generate immune monitoring reagents for Harvard Longwood medical community’s cancer vaccine trials and immune monitoring effort. In 2004 Dr Xia moved to biopharma industry, as a senior scientist first at Wyeth then principal scientist at Pfizer global biological technology focusing on antibody discovery/development and human coagulation factor bioengineering. He has played a critical role in the development of orphan drug Kanuma at Synageva as Director of Protein Engineering. He has been speakers for many national and international conferences. He authored more than 35 peer-reviewed articles, 10 US and international patents, and two-chapter books. He held multiple guest professorships with universities in Nanjing and Shanghai during 1997-2004. Dr Xia is currently the Founder and President of Abimmune Biotherapeutics LLC. A startup company in Kendall Sq Cambridge MA focusing on immunotherapy for devasting diseases such as cancer and immune-related rare diseases. He is also the cofounder and VP of Chinese Antibody Society(www.chineseantibody.org)
STEFANOS THEOHARIS
SVP Corporate Development and Partnering, Cell Medica

MIGUEL FORTE
CEO, Zelluna Immunotherapy; Chair, Commercialization Committee at ISCT

ZHINAN XIA
Founder and CSO, Abimmune Bio Previous Director, Synageva BioPharma Corp.

ZONGHAI LI
CEO&CSO, CARgen Therapeutics

JOHN LU
President & CEO of Vcanbio Center for Translational Biotechnology and Hebecell Corporation

He also serves as the Executive Vice President of Vcanbio USA and Global Head of R&D, Vcanbio Cell and Gene Engineering Corp. Ltd. Before joining VCANBIO, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas in 2016. Dr. Lu has more than 20 years of experience in stem cell and regenerative medicine, and 13 years of experience in cancer research. Dr. Lu is the inventor of more than 20 patents in stem cell field, in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, Dr. Lu’s patent application and citation ranked No. 7 and No. 5, respectively. Dr. Lu received his Bachelor of Science degree from Wuhan University (1982), Master of Medicine degree from Peking Union Medical College/Chinese Academy of Medical Sciences (1985), Master of Public Health degree from Columbia University (1988) and Doctor of Philosophy degree from University of Toronto/Ontario Cancer Institute (1992).

IMMUNOMIC THERAPEUTICS

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health.

On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ for use in the prevention and treatment of allergic diseases which resulted in over $315M in licensing revenue that year, the company has now focused on the application of its UNITE™ platform in oncology.

Website:
https://www.immunomix.com/

Product Description
Currently in Greater China and Southeast Asia, (definition, Indonesia, Philippines, Singapore and Malaysia), there are over 2.1 million suffering from cancer driven by the viral diseases Hepatitis B Virus (HBV), Epstein - Barr virus (EBV) and Human Papilloma Virus (HPV). Every year, these viruses cause another 340,000 diagnosed cancers. The UNITE™ technology platform, (UNITE), developed and validated at Immunomic Therapeutics, Inc., (ITI), is an advanced and scalable immunotherapy approach with a track record of positive human data and partnering success in the U.S. and Japan that is being successfully applied to oncology and the treatment of viraly driven cancers. ITI in CN has focused UNITE from ITI to develop therapies for HBV, EBV and HPV induced cancers. Virally driven cancers represent a $15 billion global market and the Chinese and South-East Asian opportunities specifically are likely to exceed $7 billion.

Biotech/pharma products Subsector
Nucleic Acid Drugs
Primary Therapeutic Area(s)
- Neoplasms / cancer / oncology
- Other

Phase of Development
Phase II
IPhaseBio is a clinical-stage biopharmaceutical company committed to developing improved biotherapeutics for the treatment of orphan diseases, with an initial focus on cardiopulmonary indications. Our pipeline includes therapies that leverage our proprietary elastin-like polypeptide (ELP) technology to enable less-frequent dosing and better patient compliance, as well as a reversal agent for the antiplatelet therapy ticagrelor.

Website: Phasebio.com

Primary Therapeutic Area(s)
- Cardiovascular
- Endocrine/nutritional and metabolic diseases
- Neoplasms / cancer / oncology

Product Description
PB2452, is a first-in-class reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. We are currently conducting a Phase 1 clinical trial of PB2452 in healthy subjects.

Partnering Strategy
China rights available for: PB2452 and ELP technology for peptides and proteins

QR Pharma is a specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s Disease (AD), Parkinson’s disease (PD), and other neurodegenerative disorders.

Website: http://qrpharma.com/

Product Description
QR Pharma’s candidate medicine Posiphen® targets early stage Parkinson’s Disease as well as Alzheimer’s Disease and may stop or slow the progression of those diseases. Posiphen® reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (αSYN), three proteins that can turn toxic and precipitate the onset of neurodegeneration. Posiphen® inhibits APP, tau and αSYN in tissue culture cells, mice as well as in humans. Posiphen® also shows promise in Huntington’s disease, Down Syndrome, Traumatic Brain Injury, and Post Operative Cognitive Decline. So far three clinical studies have been conducted with Posiphen®.

Primary Therapeutic Area(s)
- Diseases of the nervous system

Phase of Development
Phase 1

Ayass Bioscience is a biotech company with CLIA certified high complexity molecular genetic clinical laboratory integrated with research and development for genetic testing program and aptamer development program, based in Frisco, north of Dallas Texas.

Website: https://ayassbioscience.com/

Product Description
Ayass Bioscience was able to introduce the first diagnostic aptamer testing for D-dimer which a molecule that indicates the presence of blood clot, which the number one cause of death in the US and globally. Ayass Bioscience was able to develop the first aptamer sequence that has the effect as thrombin inhibitor and may represent a great potential first dna aptamer based blood thinner therapy. Our company was able to develop antidote as well in case of hemorrhagic side effect. Our testing was in vitro validated and ready for animal studies and clinical trials.

Partnering Strategy
We are looking to partner with pharmaceutical company moving forward toward final drug development.

NeuExcell is developing a revolutionary brain repair technology for neurological diseases. Our proprietary and patented in vivo cell conversion technology regenerates neurons from glial cells in diseased central nervous system. NeuExcell is developing two platform technologies, gene therapy and small molecule therapy, including 4 gene therapies and one small molecule in the pipeline, to treat a variety of neurological disorders including stroke, Alzheimer’s disease, ALS, spinal cord injury, Parkinson’s disease, and Huntington’s disease.

Website: https://pitchbook.com/profiles/company/160029-64

Primary Therapeutic Area(s)
- Diseases of the nervous system

Phase of Development
Preclinical
MYBIOGATE ONLINE PITCH
MEET CHINESE INVESTORS FROM YOUR OWN COMPUTERS

- Free to participate
- Every Wednesday 9am Beijing Time
- 8 mins video pitch with Chinese subtitles + 10 mins live Q&A with interpretation

WHO SHOULD PARTICIPATE?
- Investment managers, BD from large pharma and medical device companies, CRO/CMO, government reps
- 1500+ online live participants in the past 12 months
- 5000+ subscribers and 30,000+ readers of MyBioGate.com

WHO IS THE AUDIENCE?
- Medical Device companies with promising products in the China market
- Biotech and Pharma companies with preclinical to marketed products that are seeking partners in China

HOW TO PARTICIPATE?
Fill in the application on our website.
http://en.mybiogate.com/apply-now/

Contact
Feifan Zheng
feifan.zheng@mybiogate.com

CHINA FOCUS ONLINE PITCH
MEET CHINESE INVESTORS FROM YOUR OWN COMPUTERS

- Free to participate
- Every Wednesday 9am Beijing Time
- 8 mins video pitch with Chinese subtitles + 10 mins live Q&A with interpretation

WHO IS THE AUDIENCE?
1500+ online live participants in the past 12 months
5000+ subscribers and 30,000+ readers of MyBioGate.com

WHO SHOULD PARTICIPATE?
Medical Device companies with promising products in the China market
Biotech and Pharma companies with preclinical to marketed products that are seeking partners in China

HOW TO PARTICIPATE?
Fill in the application on our website.
http://en.mybiogate.com/apply-now/

Contact
Feifan Zheng
feifan.zheng@mybiogate.com

CHINA FOCUS
@JPM WEEK
Jan 8-11, 2019
San Francisco, CA

Connect with Chinese Pharma and Investors in Healthcare Innovation
Register now to get your $150 off discount
https://jpmorgan2019.mybiogate.com/
Partnership and Sponsorship
Xinxin Li
xinxin.li@mybiogate.com
+1-713-814-5022
Wechat: 276700199

CHINA FOCUS
@JPM WEEK
Jan 8-11, 2019
San Francisco, CA

MYBIOGATE RESEARCH
MISSION
INTEGRATE GLOBAL TALENTS CAPITAL TO IDENTIFY INNOVATIONS IN THE HEALTHCARE SECTOR AND DEVELOP STRATEGIC PARTNERSHIPS;

GLOBAL TRENDS;
COMPETITIVE LANDSCAPE;
DISRUPTIVE TECHNOLOGIES;
INNOVATIVE PRODUCTS;
NEW BUSINESS MODELS;
EMERGING MARKETS;
POLICY DYNAMICS;
EARLY STAGE BREAKTHROUGHS

INDUSTRY RESEARCH REPORT
CUSTOMIZED CONSULTING SERVICE

CONTACT: GINGER DING
GINGER.DING@MYBIOGATE.COM